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Model systemsThe neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, generally
with childhood onset. Despite the fact that these diseases remain fatal, signiﬁcant breakthroughs havebeenmade
in our understanding of the genetics that underpin these conditions. This understanding has allowed the
development of a broad range of models to study disease processes, and to develop new therapeutic approaches.
Suchmodels have contributed signiﬁcantly to our knowledge of these conditions. In this reviewwewill focus on
the advantages of each individual model, describe some of the contributions the models have made to our
understanding of the broader disease biology and highlight new techniques and approaches relevant to the
study and potential treatment of the neuronal ceroid lipofuscinoses. This article is part of a Special Issue entitled:
“Current Research on the Neuronal Ceroid Lipofuscinoses (Batten Disease)”.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The neuronal ceroid lipofuscinoses (NCLs), as with all neurodegen-
erative diseases, represent a highly complex biological problem. With
all challenging biological questions, model organisms, which allow the
researcher to attune the complexity of the model to the complexity of
the task at hand, represent an invaluable tool.
The NCLs are a group of lysosomal storage disorders of related
clinical pathology. They are characterised by neurodegeneration, lead-
ing to a progressive decline in cognitive and motor function, blindness
and epilepsy, eventually leading to premature death. NCLs have
traditionally been categorised based upon their age of onset but as the un-
derlying genetics of these diseases has become clearer, the NCLs are now
sub-divided based upon the causative genetic defect [1]. Individually
these different forms of NCL are rare. Together however they represent
the most common cause of childhood neurodegeneration, with an
incidence, depending upon global variation, of between 1:12,500 and
1:100,000 [2]. Given that these conditions remain fatal with few thera-
peutic options available to slowdisease progressionor ease patient suffer-
ing, they represent a signiﬁcant unmet clinical need.esearch on theNeuronal CeroidAll basic biology and pre-clinical therapeutic development requires
relevant model systems, from larger animal models for the develop-
ment of therapies and therapeutic technologies to simple single cellular
systems for the study of cell biology and system-level experimentation.
The NCL ﬁeld has developed a range of such models, which have now
been used extensively to study the biology of NCLs and to aid in thera-
peutic development. Animalmodels used to studyNCLs include classical
model systems, such as the mouse, fruit ﬂy, nematode and zebraﬁsh,
and larger animal models, including dogs, sheep and cattle. The high
degree of evolutionary conservation of some of these genes has even
allowed the development of yeast models [3].
The model organisms available to study the NCLs have been
reviewed in signiﬁcant depth previously [3]. Consequently, in this
review these contributions will only be summarised. Instead, the aim
is to provide a more detailed account of the advantages of each of
these model systems, to highlight new research ﬁndings, and to
describe new techniques and approaches likely to be of beneﬁt to NCL
researchers in the future. The availability of such a range of systems pro-
vides a unique tool kit for studying NCLs, from mammalian models for
disease pathology and therapeutic development to simpler systems
allowing a more detailed understanding of basic biology. The unique
features of these individual models form the main focus of this review.
2. Large animals
Numerous naturally occurring large animal models of the different
forms of NCL have been described since the ﬁrst report in two English
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the dog, but the disease has also been reported and studied in other
species such as cattle, horses, pigs, goats, cats, ferrets, birds andmonkeys.
The study of thesemodels has largely contributed to a better understand-
ing of the pathophysiology of the disease. Despite themore recent devel-
opment of geneticallymodiﬁedmousemodels, these large animalmodels
are still valuable. The anatomy of their gyrencephalic brain is closer to
human brain anatomy than the lissencephalic brain of rodents. Conse-
quently, the phenotype of these affected animals more closely mimics
the clinical signs of NCL observed in humans with their longer lifespan
allowing a more thorough evaluation of potential therapeutic strategies.
For these reasons, large animal models are an excellent complement to
laboratory animals. The following section will describe NCL pathology in
these models and illustrate their importance to our understanding of
the pathophysiology and biochemistry of the NCLs. For brevity, the
other large animal affected by NCL will be summarised and referenced
in Table S1.
3. Modelling NCLs in large animals
The disease was ﬁrst described in a ﬂock of South Hampshire sheep
in New Zealand in 1976 by Jolly and West [5]. The clinical signs start at
7months of age and are usually early signs of blindness that is initially of
cerebral origin but as the disease progresses retinal degeneration
become more apparent. As the animal ages, other signs such as ataxia
and decreased mentation become apparent and, in later stages, partial
seizures occur before death by two years of age [6,7]. The disease is
caused by a mutation in CLN6 [8–10] and another mutation in the
same gene causes similar pathology in Merino sheep [9,11].
A similar phenotype affecting Borderdale sheep was reported in
2002 by Jolly et al. [12] and a colony was established. The causative
mutation was found in CLN5 [13], which is mainly responsible for the
late infantile form of NCL in humans formerly known as the “Finnish
variant” [14].
A form of NCL affecting newborn White Swedish Landrace Sheep
was reported on a Swedish experimental farm [15]. The main clinical
signs include tremors and weakness, an inability to suckle and marked
cerebral atrophy [15]. A mutation in the cathepsin D gene was later
identiﬁed [16,17]. Interestingly, a mutation in this gene was subse-
quently identiﬁed in a newborn infant with severe microcephaly and
was assigned CLN10 [18].
Multiple forms of NCL have been described in numerous breeds of
dogs. In most cases these have been sporadic descriptions of clinical
cases and only a few colonies have been established and studied as
animal models for NCL research.
The English Setter was the ﬁrst described animal model of NCL and
most canine studies were performed in this breed. The clinical signs
start at 14–18 months and are characterised by decrease mentation,
ataxia and blindness. Convulsions occurred a few months later and no
animal survived to more than 26 months of age [19]. A mutation in
CLN8 was identiﬁed as the cause of the disease in this breed [20]. The
research colony is no longer active, but frozen semen has been stored
[21].
At least three different forms of NCL have been reported in
Dachshunds. The ﬁrst one, in longhair Dachshunds, is caused by amuta-
tion in the TPP1 gene (CLN2). Progressive neurological signs includemen-
tal retardation, ataxia, blindness and general myoclonus by 9 month
of age [22]. A research colony has been established [23], which to the au-
thors' knowledge, is the only currently available canine colony. In people,
mutation in CLN2mainly results in a classic late infantile form,withmen-
tal retardation, epilepsy and vision deﬁcits [14,24].
NCL has also been reported in numerous other species including
cows [25], monkeys [26], ferrets [27], cats [28,29], pigs [30], goats [31],
horses [32] and birds [33,34]. Speciﬁc mutations are listed in Table S1.
Similar to humans with NCL, the main gross pathological ﬁndings in
large animals consist of different degrees of cerebral and cerebellaratrophy [19,35–37]. Histopathologically, there is neuronal loss and
astrocytosis accompanied by the accumulation of autoﬂuorescent stor-
age material that is the hallmark of the NCLs. The South Hampshire
sheep played a key role in the identiﬁcation of subunit c ofmitochondri-
al ATP synthase as a major component of the storage material in some
forms of NCL [38,39] and was also used to demonstrate that the degree
of neurodegeneration is not correlated with lipopigment accumulation
[40]. Due to their relatively complex cortex, sheep models of NCL have
been used to study the selective and sequential degeneration of
GABAergic interneurons in different regions of the brain [40]. A regional
neurodegeneration in GABAergic neurons was also reported in the
English Setter dog model [41]. Impaired neuronal synaptic function
has also recently been reported in cell culture from sheep with CLN6
mutation [42].
Recent studies suggest that impairedmetal ion homeostasis plays an
important role in the pathophysiology of different neurodegenerative
diseases [43] and a similar ﬁnding has been reported in Merino and
South Hampshire sheep carrying CLN6 mutations [44]. This could be
secondary to the progressive loss of themetal transporter Zip7 observed
in the affected sheep [45] and connected with the increases in levels of
α-Synuclein, implicated in Parkinson's disease, and themetal transport-
er ATP13A2, which is mutated in an inherited form of early-onset
Parkinsonism [45,46]. Increased levels of superoxide dismutase were
all seen in these sheep and likely reﬂect chronic oxidative stress.
Taken together, ﬁndings from the sheep models point to chronic neural
inﬂammation as an important part of the disease process, as is thought
likely for other neurodegenerative disorders.
Large animal models have greatly contributed to the understanding
of the pathophysiology of blindness,most particularly the retinal chang-
es. Multiple functional, histopathological and ultrastructural studies
have been performed in different large animal models and although
most animal models show retinal changes, there is variability in the
severity and distribution of the histopathological changes and their
associated functional consequences. Dachshunds with CLN2mutation
[23,47], Polish Owczarek Nizinny dogs [48,49], Miniature Schnauzer
[50], Devon cattle (CLN5) [51] and South Hampshire sheep (CLN6) [7,
52–54] show marked retinal atrophy and loss of the rod and cone
layer with associated electroretinographic changes, in line with obser-
vations in humans with mutations in the same genes [55]. In contrast,
English Setters (CLN8) [54,56,57], American bulldogs (CLN10) [58] and
Dalmatians [54,59] show less severe retinal changes and the photore-
ceptor layer is not affected, which again mirrors the presentations in
humans with these mutations [55]. Despite its late onset form, Tibetan
terriers (ATP13A2) [60] also show marked retinal and photoreceptor
changes at a more advanced stage of the disease.4. Large animal models: a therapeutic focus
Depending on the form of NCL, different therapeutic approaches
have been considered, including various forms of enzyme replacement
therapy (ERT) and gene therapy, and large animal models have proved
invaluable for pilot studies. Initially, haematopoietic cell transplantation
was attempted in the English Setter (CLN8) and SouthHampshire sheep
(CLN6) but with no effect on disease progression [61,62]. This approach
was unlikely to succeed considering the transmembrane nature of the
deﬁcient protein in these forms of NCL, although a recent abstract
suggests that intercellular correction occurs in chimeric sheep created
by merging blastomeres from normal and CLN6 affected embryos [63].
However, in forms of NCL resulting from deﬁciencies in lysosomal
enzymes, such as CLN1, CLN2 and CLN10 diseases, direct supplementa-
tion can be considered. Dachshunds lacking the tripeptidyl peptidase-1
enzyme (TPP1, or CLN2) represent an excellent model for this type of
strategy. Early studies suggest that intrathecal or intracerebroventricu-
lar administration of recombinant human TPP1 can delay the clinical
signs [64].
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peutic approach that has shown promising results in ovine CLN5 neuro-
nal cell cultures [65]. Initial studies in unaffected sheep conﬁrmed
extensive protein expression from the AAV9 vector [66] and the ﬁrst
results from dogs (CLN2 Dachshunds) showed that viral transduction
resulted in an increased enzymatic activity and delayed clinical progres-
sion [67]. Directed therapy to treat retinal degeneration in CLN2 Dachs-
hunds by implanting genetically modiﬁed autologous bone marrow
stem cells into the eye is now being developed, with some positive
initial results [68].
Large animal models are potentially very useful to test drug thera-
pies. Palliative treatment with the anti-inﬂammatory minocycline that
is currently in human clinical trials was assessed in a sheep model
of NCL (South Hampshire, CLN6) but showed no ability to inhibit
microglial activation or astrocytosis [69]. However, for interventions
to be assessed quantitatively for therapeutic efﬁcacy, more accurately,
longitudinal biomarkers for disease progression are necessary. To this
end, recent studies have focused on characterising the behavioural
changes in these animal models more accurately [70,71].
5. Mice
Historically, mouse models of neurodegenerative genetic disease
have played a pivotal role in attempts to understand the neurobiology
underpinning these complex disorders. They represent a logical pro-
gression from ﬂy or zebraﬁsh models as a more complex mammalian
system with a greater genetic, anatomical and physiological similarity
to human patients. They are easy to handle, have a high reproductive
rate and are relatively cheap compared to other mammalian model
systems. Such mouse models may arise through natural de novo muta-
tion, induced random mutagenesis or by targeted molecular biology to
disrupt a particular gene or genomic locus. The resolution of such
disruptions can vary from deletion of multiple exons from a gene of
interest to speciﬁc point mutations that accurately mimic the genetic
defect in patients. There is no guarantee that the introduction of mu-
tations to the mouse version of the gene will accurately recapitulate
a phenotype similar to that observed in the patient population.
However, if they do then this represents an extremely powerful
biological tool.
Mouse models that faithfully recapitulate andmimic the human form
of the disease have beenused to conﬁrm the role of candidate genes in the
disorder. They can be used to study the underlying mechanism and
progression of the disorder and this information can be used to design
urgently required novel therapies or improve on existing ones. The iden-
tiﬁcation of reliable biomarkers remains a high priority area in the neuro-
degenerative disease ﬁeld and mouse models of disease provide an ideal
resource in which to search. Finally, the model itself can be used to test
potential novel therapies and small molecule drugs — do these have any
disease modifying effects in the model, do they ameliorate the disease
symptoms and pathology and do they rescue the model from premature
death? Essentially, this is a fundamental species inwhich pre-clinical test-
ing of therapies can take place before moving onto a larger model of the
disease (if available) or moving directly into the clinic. The NCL ﬁeld has
greatly beneﬁted from investment and a strategy to generate mouse
models of the various forms of the disease.
6. Modelling NCLs in mice
There are currently 12mouse models of NCL: Cln10mouse [72], two
Cln1 mice [73,74], Cln2 mouse [75], Cln5 mouse [76], Cln6 mouse [77],
Cln8 mouse [78], four Cln3 mice [79–82] and most recently a Cln7
mouse [83]. The reader is referred to a comprehensive review for details
of the various features of the mouse models of NCLs with the exception
of the recent Cln7mouse [84]. In addition to these bona ﬁdemodels of
NCLs, there are other candidate mouse models that display features
that resemble human NCL symptoms. These include null mutationin genes for ctsf [85], Ppt2 [73,86] and the chloride ion channels
Clcn-6 [87] and Clcn-7 [88]. However, it should be noted that none
of these candidate models can be linked directly to established
human forms of NCL.
An obvious starting point of investigation in the NCL mice is the
characterisation of temporal and spatial CNS pathology. All the models
display the characteristic accumulation of ﬂuorescent material and
brain pathology and, where investigated, retinal involvement and pre-
maturemortality. However, there are also often both obvious and subtle
differences between models of the different forms of the disease.
Furthermore, there can be differences between the models of the
same form of the disease. The four models of CLN3 disease provide a
good example of this. The different mutations in the same gene lead to
differences in the age of neurological symptom onset ranging from
less than two months [80] to 16 months [82]. It is worth noting
that this may be due to residual CLN3 activity due to variant mRNA
transcripts [79] also reported in patient samples [89]. The Cln3 mice
also differ from the other models in that although there is subtle activa-
tion of glial cells, there is not the prominent astrogliosis-associated prolif-
eration or macrophage formation [90,91].
7. Mouse models: a therapeutic focus
The production and characterisation of themodels have undoubt-
edly furthered our understanding of the disease in its various forms
and are ongoing processes. Perhaps the greatest value of the infor-
mation gathered lies in the development of novel therapies. Any
such endeavour requires knowledge of: (1) whether the mouse
model is a reliable tool for therapeutic efﬁcacy i.e. does the model
faithfully recapitulate the symptoms observed in patients; (2) the
target e.g. a particular cell type or receptor; (3) when the therapeutic
agent should be administered i.e. the therapeutic window of oppor-
tunity; and (4) where it is required to be administered i.e. localised
to one particular area or a broader anatomical distribution. There is
also the issue of selecting the most practical and suitable model for
the desired experiment. For example, if a drug requires administra-
tion twice daily to a Cln3 mouse to measure delay of neurological
onset or increase in survival, then the investigator may be advised
to select the model that shows symptoms at 2 months rather than
16 months. It is clear that the vast majority of novel therapies have
been tested in those models of NCLs that are associated with a defec-
tive or absent soluble enzyme. This includes ERT, stem cell and gene
therapies.
ERT has an established history in the lysosomal storage disorder
(LSD)ﬁeld and has revolutionised the treatment of patients e.g. Gaucher
disease. The drawback is that intravenously administered recombinant
enzyme may have a limited ability to cross the blood–brain barrier
and so treating the CNS has proved difﬁcult. However, high doses of
intravenously administered recombinant Ppt1 enzyme have been
shown to ameliorate pathology in the thalamic region of the brain in
Cln1mice leading to a subsequent later onset ofmotor function deteriora-
tion and extended survival. The effects of this approach are enhanced if
therapy is initiated in the mice from birth [92] and highlights the impor-
tance of intervening within the optimal therapeutic window of opportu-
nity. Similarly, the mouse model of Cln2 has also demonstrated
amelioration of CNS pathology, reduced neurological symptoms
and extended lifespan following intrathecal and intraventricular admin-
istration of recombinant Tpp1 enzyme [93,94]. Encouragingly, this data in
CLN2mice has contributed to the initiation of a Biomarin Pharmaceuticals
sponsored phase I/II clinical trial of recombinant Tpp1 enzyme (BMN-
190) administered to patients with CLN2 disease via intracerebroventric-
ular infusion (ClinicalTrials.gov identiﬁer: NCT01907087).
The recent ascendency of the gene therapy ﬁeld has led to a number
of successful clinical trials including paediatric neurological conditions
such as X-linked adrenoleukodystrophy and metachromatic leukodys-
trophy [95,96] and themousemodels of NCL have been used to evaluate
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primarily been focused on the use of adeno-associated virus (AAV)
gene delivery vectors that carry a therapeutic fully functional version
of the defective gene and are administered directly into the brain. Prom-
ising results have been demonstrated in Cln1 [97–99], Cln2 [100–102]
and Cln10 mice [103,104] resulting in reduction of disease pathology
and extension of lifespan. It is very likely that continued improvements
in AAV vector design and production will lead to further enhancements
in therapeutic efﬁcacy and knowledge of themousemodel pathology is
vital for this process. For example, targeting a particular cell type may
dictate which particular serotype of AAV should be used andwhich pro-
moter should be included to provide optimal expression of the deliv-
ered therapeutic gene. Knowledge of the areas of the brain that are
affected is also vital to ascertain where the vector should be delivered,
or indeed, if multiple sites of administration are required. Finally, an
understanding of the timing of disease progression will inﬂuence at
what stage the vector should be administered. The critical issue of inter-
vening early and even pre-symptomatically has been demonstrated in a
Cln2mouse [100] and advantages of perinatal gene therapy have been
recognised for some time [105,106]. This is perhaps most critical in
the context of acute paediatric neurodegenerative diseases where
neuronsmust be rescued prior to irrevocable loss. The promising results
observed in the CLN2mice led to a gene therapy clinical trial in patients
[107].
Finally, stem cell therapies have also been tested in mouse models.
Human neural stem cells have been administered to the brains of neo-
natal Cln1 mice that have been crossed with immunodeﬁcient severe
combined immunodeﬁciency (SCID) mice to avoid rejection [108]. Ben-
eﬁcial effects included a reduction in autoﬂuorescentmaterial and delay
in motor function deterioration. These ﬁndings led to a phase I clinical
trial in CLN1 and CLN2 patients that showed that transplanted cells
did not trigger any adverse effects and supports further investigation
[109].
Comparatively less progress has been made in developing treat-
ments in the mouse models that mimic the defects in transmembrane
protein forms of NCL. They do represent a more difﬁcult target com-
pared to the soluble enzymatic forms — they cannot be secreted and
recaptured by neighbouring cells making cross-correction void. This
effectively excludes ERT as a realistic approach. Gene therapy is still a
viable therapeutic option but will probably require much higher levels
of transduction. However, a recent study has shown that AAV-mediated
gene delivery to the brains of neonatal Cln3mice has a therapeutic beneﬁt
leading to a reduction in storage material, gliosis and evidence of
improved neuron counts [110]. Pharmacological therapies have also
been tested in CLN3 mice including NMDA and AMPA receptor antago-
nists that lead to improved motor function [111,112].
The contribution that the current repertoire of NCL mouse models
available has had on furthering our understanding of this group of
diseases is huge. This is evident from the continual investigation into
new therapies, many of which have made their way to clinical trial.
This is very encouraging and strongly supports continued investment
of resources into the study and use of these models but also the gener-
ation of novel models.
8. Zebraﬁsh
Zebraﬁsh are small freshwater ﬁsh that have for many years been an
important research tool. While previously used predominantly by
developmental biologists, zebraﬁsh are now established as a vertebrate
disease model, and are increasingly being used to study neurodegener-
ative disease. The zebraﬁsh genome can be easily manipulated and the
availability of the latest reference assembly (GRCz10) on bioinformatics
databases further supports its use. Orthologues of all NCL-causing genes
exist in zebraﬁsh and are highly conserved; in some cases more than
one copy is present due to duplication of an ancestral locus during
evolution [113].Zebraﬁsh have many useful characteristics for disease modelling:
they are vertebrates and therefore more similar in their development
and physiology to mammals than other model organisms such as fruit
ﬂies; a single pair can produce several hundred rapidly-developing
offsprings per week, meaning that statistically signiﬁcant sample sizes
can be reached quickly and larval development is transparent, enabling
high quality imaging techniques to be used to view the developing
animal [114].
Drug-target validation is a highly advantageous feature of
zebraﬁsh, enabling simultaneous toxicity and efﬁcacy testing in a
whole organism. Disease phenotypes manifest early in development
and phenotypic endpoints may include behavioural testing or the
monitoring of ﬂuorescent reporters, for example [114]. Importantly,
candidate compounds can be delivered by simple addition to the
tank water. Illustrative of the potential of zebraﬁsh for drug discov-
ery is the identiﬁcation of the ﬁrst bone morphogenetic protein
inhibitor, a derivative of which successfully treats ﬁbrodysplasia
ossiﬁcans progressiva [115]. In addition zebraﬁsh research led to
the identiﬁcation of a number of modiﬁers of gluconeogenesis
[116] and the repurposing of leﬂunomide (previously a treatment
for rheumatoid arthritis) to suppress melanoma [117].
Large-scale mutagenesis screens have highlighted approximately
2000 genes involved in development [118,119] and mutations in
many genes relevant to neurological disease (including NCLs) continue
to be found [120]; many of these alleles are currently available through
the Wellcome Trust Sanger Institute, Hinxton, UK.
For quick, proof-of-principle enquiries into the function of
zebraﬁsh orthologues of human disease-causing genes, oligonucleotide-
based knockdown studies are invaluable but suitable controls are essen-
tial [121]. Phenotypes are generally observable before 5 days post
fertilisation. Following initial analysis, knockout animals can also
be generated for research in more stable systems.
Both zinc-ﬁnger nucleases (ZFNs) [122] and transcription activator
like endonucleases (TALENs) [123] have successfully knocked-out
zebraﬁsh genes. The current tool of choice is the Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)-associated system
that uses the Cas9 nuclease to generate breaks or nicks in the chromo-
some [124]. This method also shows promise for the development of
disease-speciﬁc knock-ins and the humanisation of zebraﬁsh with
healthy or mutant genes [125].
It should be noted that in some cases, phenotypes will either not
develop or will manifest late in development. This may arise either
due to redundancy in biological pathways or because physiological
difference between zebraﬁsh andmanmean that pathological phenom-
ena such as lipofuscin accumulation are unable to develop. For example,
autoﬂuorescent lipofuscin is undetectable in the zebraﬁsh model of
CLN2 disease, although many other features representative of the
disease do exist [126].
9. Modelling NCLs in zebraﬁsh
To date, six zebraﬁshmodels of LSDs have been published but several
are undergoing development; three of these are NCL models including
CLN2, CLN10 and CLN11. These and other models for NCLs, are catalogued
in Table S2.
CLN2 disease is caused bymutations in TPP1, encoding the lysosomal
hydrolase tripetidyl peptidase (TPP1). The zebraﬁsh model of CLN2
disease carries amissensemutation leading to a premature termination
codon and complete loss of enzyme function. The lack of functional
lysosomal Tpp1 leads to a number of phenotypes relevant to human
disease including early neurodegeneration, reduced neurogenesis,
epileptic seizures, motor abnormalities, visual defects and premature
death [126].
CLN10 disease is similarly caused by mutations in a lysosomal hydro-
lase, cathepsin D (CTSD). In humans CLN10 disease is very severe, causing
congenital defects. The zebraﬁsh model of CLN10 disease was generated
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eyes due to the absence of retinal pigmented epithelialmicrovilli, disorga-
nized musculature and premature death [127]. This model also exhibits
lack of yolk resorption, a process reliant on autophagy and, by
extension, lysosomal function. Mis-regulation of autophagy is thought
to contribute to most neurodegenerative diseases.
Mutations in GRNA, encoding granulin, cause CLN11 disease. Two
groups have knocked-down grna, although neither group has validated
the model with respect to CLN11 disease. However, they observed
motor neuron truncation and abnormal CNS development [128,129].
Given that in humans, autosomal dominant GRNA mutations cause
fronto-temporal lobar degeneration, a motor neuron disease variant,
these phenotypes require further investigation.
CLN3 disease is caused by mutations in CLN3, encoding a lysosomal
transmembrane protein of unknown function. Data presented at a num-
ber of international conferences have described a zebraﬁsh model of
CLN3 disease generated by morpholino knockdown. This model exhibits
small eyes, greatly disorganized neuronal axon pathﬁnding, astrocytosis,
lysosomal storage of subunit c of mitochondrial ATP synthase, epileptic
seizures, motor abnormalities and premature death (Wager at al.,
submitted).
10. Zebraﬁsh models: a therapeutic focus
As highlighted above, zebraﬁsh research has been used to directly
inform therapy but as a relatively simple model, it is perhaps more
ideally suited for the analysis of basic biological processes relevant to
therapy. Although NCL research in zebraﬁsh is a recently established
ﬁeld, zebraﬁsh have a much longer history of use for studying neurode-
generation as a whole, and comparative analysis of related disease
models can be of signiﬁcant value in informing therapy in a range of
conditions.
There are a range of established zebraﬁshmodels for neurodegener-
ation. Zebraﬁshmodels for Alzheimer's disease include amyloid precur-
sor proteinmorphants [130] and amyloid beta transgenic animals [131].
Aberrant phenotypes in zebraﬁshmodelling Alzheimer's disease include
disorderedmovement. Transgenic models of tauopathy are also available
[132,133], which display both Tau accumulation and tangle formation,
and Tau phosphorylation. There are also awide range of models available
to study Huntington's and Parkinson's diseases and amyotrophic lateral
sclerosis (ALS).
Huntington's models include huntingtin transient overexpres-
sion models [134], transgenic animals [135] and morphants [136].
Studies in these models indicated protein aggregation, apoptosis,
increased rhodopsin expression, developmental defects and embry-
onic lethality. Interventions such as inhibition of nitric oxide produc-
tion and methylene blue treatment reduced aggregates in some of
these studies.
ALS models include Sod1 mutant overexpression [137] and trans-
genic models [138]. Other models include Tardbp mutant overex-
pression, transgenic or morphant animals [139,140] and Fus
transgenic animals [140]. These models display motor neuron and
neuromuscular junction defects. Studies have indicated a rescue of
these defects by upregulation of Vegf [137] or by methylene blue
treatment [140].
Parkinson's disease is probably the most broadly modelled neu-
rodegenerative disease in zebraﬁsh. Models include, Park2 [141],
Pink1 [142–144], Park7 [145] and Lrrk2 [146] and cover morphant,
transgenic and TILLING mutant models. Pharmacological models
can also be obtained by MPTP exposure [147,148]. Increased
susceptibility to cellular stress and mitochondrial changes are
common features of these models, and many recapitulate dopami-
nergic neuronal loss.
A range of other neurodegenerative diseases have also been
modelled, including frontotemporal dementia [149], spinal muscular
atrophy [150,151] and hereditary spastic paraplegia [152]. Suchmodelsrecapitulate many aspects of these diseases, such as spinal motor neu-
ron defects and associated behavioural changes. The successful model-
ling of multiple neurodegenerative diseases in zebraﬁsh highlights its
relevance as a model for NCLs. Further, the interventions that have
been used in these models to correct defects associated with neurode-
generation could inform future NCL research.
11. Fruit ﬂy
For more than a century Drosophila has been at the forefront of
research into genetics, inheritance and development. A huge arsenal
of genetic tools has been developed over that time and new tools
continue to be developed that help to maintain the status of Drosophila
as a key model for studying fundamental mechanisms. More recently,
these powerful genetic tools combined with the short generation time
(10 days) and simple, cheap animal maintenance requirements have
made Drosophila an attractive tool to model human disease. Approxi-
mately three quarters of human genes associated with disease are
conserved in the Drosophila genome [153] and many inherited diseases
have now been modelled in Drosophila. Although small in comparison
to mammals, the Drosophila CNS shares many fundamental properties
with the CNS of higher eukaryotes: it is isolated by a blood–brain barri-
er; neuron–glia interactions are critical for function and numerous neu-
rotransmitters are used in different contexts, including glutamate,
acetylcholine, dopamine, GABA and various peptidergic neurotransmit-
ters. The adult Drosophila CNS also governs complex behaviours includ-
ing mating routines, memory and learning, circadian rhythms, sleep,
walking behaviour and ﬂight navigation. Importantly, aspects of neuro-
pathology are also similar, meaning that Drosophila has been used to
investigate the cell biology of many of the common neurodegenerative
diseases of humans, including both gain-of-function disorders, such
as tauopathies and triplet expansion diseases, and loss-of-function
diseases, such as inherited forms of Parkinson's disease (reviewed in
[154–157]).
12. Modelling NCLs in Drosophila
In common with other invertebrates, Drosophila melanogaster has
only a subset of the disease genes known to cause NCL in humans.
These encode the lysosomal enzymes Ppt1 (CLN1) and cathepsin D
(CLN10), the endo-lysosomal membrane proteins, CLN3 and CLN7
(also known as MFSD8, encoded by CG8596 in Drosophila), and the
synaptic vesicle protein cysteine string protein (CSP or CLN4). Addition-
ally, Drosophila has genes encoding likely lysosomal chloride channels,
including CLC-7 (CG8594), which is associatedwith NCL-like accumula-
tion of lipofuscin and neurodegeneration [88]. Loss-of-function models
have been generated for Ppt1 [158], cln3 [159], cathD [160] and cln7
(Megan O'Hare, Richard Tuxworth and Guy Tear, unpublished) to
study cell biology of the NCLs. In contrast,Drosophila Csp has been stud-
ied extensively not as an NCL disease locus but rather for its functions at
the synapse [161,162], reviewed in [163]. Recent reviews have covered
many of theﬁndings fromNCL studies usingDrosophila and the reader is
referred to these (see [84,164]). Information and annotation of the Dro-
sophilaNCL genes, details ofmutant alleles and transgenic constructs for
each gene, ﬂy lines and reagents available from the stock centres and all
papers referring to NCL genes can be found on FlyBase (www.ﬂybase.
org). Instead, this perspective will focus on some of the techniques
and tools developed more recently in Drosophila that could be used to
help understand aspects of NCL cell biology in the future, including
newly developed synaptic labelling tools and CRISPR-mediated genome
editing.
The Drosophila research community was quick to adopt the CRISPR
method of genome editing. CRISPR was adapted from a defencemecha-
nism in the bacterium Streptococcus pyogenes and involves a nuclease,
Cas9, being directed to a speciﬁc genomic location by a short (20 bp)
guide RNA where it is generates double-stranded breaks (DSBs) in the
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non-homologous end joining (NHEJ), which results in insertions and
deletions (indels), or homology-directed repair (HDR) by copying
from a supplied template. HDR allows for insertions, base changes or
other editing events to be included at the site. Simply change the
guide RNA sequence and the mutations are directed elsewhere in the
genome [165,166].
More than 20 papers have been published in the last two years
detailing strains, reagents and approaches to improve CRISPRmutagen-
esis in Drosophila (reviewed in [167]) and it is fast becoming a standard
technique. Drosophila strains are available which express various forms
of Cas9, including amutated form that cannot generate DSBs so repair is
biassed towards HDR, and forms driven by various different promoters
to improve efﬁciency. Numerous plasmids and other reagents have
also been generated and made available via stock centres while proto-
cols to test gRNA sites for efﬁciency of have been developed. CRISPR
genome editing is also being combined with older genomic technolo-
gies such Recombination-Mediated Cassette Exchange (RCME) that
enables rapid insertion of different cassettes into a single CRISPR-
modiﬁed genomic strain, for instance to tag a gene with different ﬂuo-
rescent proteins or to generate conditional alleles [168].
The importance of CRISPR genome editing for research into the cell
biology of the NCL disease genes in Drosophila is difﬁcult to underesti-
mate. By inserting sequences encoding ﬂuorescent proteins or epitope
tags into NCL gene loci the requirement for high afﬁnity antibodies
can be by-passed— a particular advantage for transmembrane proteins
such as CLN3 and CLN7 that have proved poorly antigenic. Knock-in
reporters will also circumvent a common issue encountered when
vesicular proteins are fused to reporters and overexpressed: the protein
sorting pathways can be swamped and the fusion protein found inmul-
tiple locations in the cell as a consequence. CRISPR could be used to
knock-in molecular hooks for proteomics studies; genetically encoded
reporters for cellular physiology studies; new markers for lysosomes
can be generated; point mutations mirroring those found in human
patients could be engineered into genes. While CRISPR technology will
also provide these opportunities in other models and systems, the
generation time of Drosophila will enable new in vivo reagents to be
generated and combined with existing tools and reagents very rapidly.
If the correct question is asked, CRISPR genome editing in Drosophila
should speed up research into the cell biology of the NCLs dramatically.
13. Drosophilamodels: a therapeutic focus
Being a relatively simple model system,Drosophila are ideally suited
to the analysis of the pathways that inﬂuence disease. Modiﬁer screens
are an established technique in the Drosophila ﬁeld. Brieﬂy, candidate
screens or larger scale, random screens are performed to identify
genes that modify a phenotype (usually when made heterozygous or
when overexpressed). The phenotype needs to be easily scorable for
higher throughput so degeneration present in the adult eye is often
used as it can be seen with a dissection microscope. This approach has
been used successfully to identify genes modifying phenotypes relating
to Ppt1 [169] and cln3 [170]. These screens highlighted likely functions
regulating endocytosis for Ppt1 [171], in stress signalling for Cln3
[159] and in JNK signalling for both Ppt1 [171] and Cln3 [170]. More
recently, new collections of RNAi lines have been generated for most
genes in the Drosophila genome (www.ﬂyrnai.org/TRiP-HOME.html).
These lines complement previous collections and allow for very efﬁ-
cient, cell-type speciﬁc knock-down of gene expression via the UAS-
GAL4 bi-partite expression system. A small candidate gene approach
for the NCLs genes in Drosophila using some of these reagents has iden-
tiﬁed potential connections between Ppt1, cln3 and Cisd2 (also known
as Wfs2), which is mutated in Wolfram syndrome [172]. Wolfram
patients develop childhood-onset optic atrophy and diabetes mellitus,
usually followed by neurodegeneration. The cellular events that under-
pin the disease are perhaps better understood for Wolfram syndromethan for the NCLs and endoplasmic reticulum stress is considered a
major component [173]. Increases in ER stress markers have been
reported previously in NCL studies [174,175] and this type of genetic
interaction study points to the common features in the cell biology
underpinning different neurodegenerative syndromes.
Synaptopathy – synaptic dysfunction associated with pathology— is
an early hallmark of many neurodegenerative diseases and usually
precedes overt neuronal loss. Synaptopathy also occurs in NCL models
[176]. Given the early onset of neurodegeneration in theNCLs, it is likely
that some of the CLN genes play a role in the development of the
nervous system and/or the stability of synapses. The neuromuscular
junction (NMJ) synapse of the Drosophila larva is an established model
used to study synaptic development, composition, function and plastic-
ity [177]. Motor neurons in Drosophila, in contrast to mammals, are
glutamatergic and their synapses are structurally similar to central synap-
ses of the mammalian CNS. However, unlike mammalian CNS synapses,
they can be made readily accessible for electrical recordings and high-
resolution microscopy by simple dissection (reviewed in [178–180]).
The functions of several conserved components of synapses were eluci-
dated in studies on the Drosophila NMJ, including those of CSP [161,
162]. Recently, super-resolution microscopy studies of the larval NMJ
have provided exquisitely detailed information about the structure of
synapses that will likely hold true for the mammalian CNS [181].
Changes in the electrical properties of larval motor neurons have
been reported in Drosophila lacking Ppt1 function resulting in a locomo-
tion deﬁcit for the larva [182]. The phenotypes are rescued by re-
expressing Ppt1 speciﬁcally in the nervous system, demonstrating that
Ppt1 is required only pre-synaptically and consistent with a role in syn-
aptic vesicle endocytosis. No changes were seen in the size of synapses
in Ppt1mutant larvae but they are present in larvae lacking either cln3
or cln7 function along with changes in locomotion (Megan O'Hare,
Richard Tuxworth and Guy Tear, King's College London, unpublished
observations). The size of the synapse is closely controlled by homeo-
static mechanisms that match pre-synaptic innervation with the
requirements of the post-synaptic muscle so the changes in synapse
size indicate possible alterations to synaptic activity in these mutants
which warrant further examination. Similarly, a careful assessment of
the NMJs in cathD mutant larvae may also reveal synaptic functions
for cathepsin D.
By far the best understood of all theDrosophilaNCL genes is Cspwhich
was originally identiﬁed as a component of synapses via amonoclonal an-
tibody screen [183]. There is only one Csp gene inDrosophilawhich corre-
sponds to the CSPα form in mammals. CSP is a palmitoylated protein
containing a dnaJ chaperone-like domain and, given the function of
PPT1 as a depalmitoylating enzyme, CSP is potentially a substrate of
Ppt1. Cspmutants in Drosophila display severe defects in neurotransmis-
sion [161,162,184] and it will be of interest, therefore, to determine
whether combining Csp and Ppt1mutations exacerbates either synaptic
phenotype.
The larval NMJ of Drosophila has been used extensively to study
synaptic development in part because individual synapses and even
sub-synaptic structures such as active zones can be visualised and quan-
tiﬁed [178]. Many genes involved in human neurological disease have
been shown to affect synapse number at theDrosophilaNMJ but wheth-
er similar changes occur in the CNS – and thereforemight also be occur-
ring also in human neuropathology – is much more difﬁcult to answer.
Neurons in the insect CNS are tightly packed in a neuropil and individual
synapses and active zones cannot be visualised so easily. Traditionally,
serial scanning electron microscopy studies have been used to look at
synapse number in neurodegenerative disease post-mortem tissue but
these are laborious and can cover usually only small areas of the CNS.
However, the development of genetic tools to label synapses in
Drosophilamay help to address these issues in the future. A recent light
microscopy technique, Synaptic Tagging with Recombination (StaR)
developed for Drosophila by the Zipursky lab [185] allows pre-synaptic
active zones or post-synaptic receptor clusters to be labelledwith epitope
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small enough subsets that individual synapses can be visualised. A cell-
type speciﬁc “ﬂip-out” technique governs which neurons are labelled.
This type of approach ﬁts well with the Fly Light project at HHMI Janelia
Farm Research Institute that has generated thousands of lines to control
transgene expression in small subsets of neurons within the Drosophila
CNS [186] (seewww.janelia.org/team-project/ﬂy-light). Looking forward,
it seems possible that we will be able to ask what happens to synapse
number in Drosophila NCL and other neurodegeneration mutants in
development and, potentially, as ﬂies age and neurodegeneration
progresses.
14. Yeast
Yeast are an invaluable tool for the study of eukaryotic cell biology.
Yeast species have been utilised for decades to study basic cellular pro-
cesses, such as cell division, protein and membrane trafﬁcking and cell
signalling. Yeast were also the ﬁrst post-genomic eukaryotic model
[187], highlighting its regard as a key system in basic biology, and also
many of the current advantages that yeast species afford.
There are two commonly used yeast model systems, the budding
yeast Saccharomyces cerevisiae and the ﬁssion yeast Schizosaccharomyces
pombe. Although ﬁssion yeast has been used as a model system for a
shorter period of time, both have similar tools and advantages. Their sta-
tus as long-standing post-genomicmodels has allowed an understanding
of the yeast genome in exceptional detail. This detailed genomic under-
standing has afforded an equally detailed analysis of the yeast tran-
scriptome and proteome, allowing truly quantitative analysis of these
omic proﬁles [188], the characterisation of these proﬁles under different
conditions and the inﬂuence of different regulatory processes [189]. This
understanding has also been coupled with in silico techniques to predict
and identify functional protein domains [190], predict protein interaction
networks [191,192], and to expand our understanding of metabolic
processes [193]. Importantly, all this information is integrated into com-
prehensive genome databases [194,195], providing an exceptional level
of information about a gene of interest before a single experiment need
be performed.
Another product of this advanced understanding is the presence of a
wide range of functional genomic tools. Some of the most widely used
and valuable of these tools are the yeast gene deletion collections
[196,197]. Importantly, these resources provide a platform for many
technologies that are relevant to the study of disease. The combination
of a genomewide-deletion collection, classical yeast genetic approaches
and robotic technologies has facilitated the development of new func-
tional genomic techniques. One of the most popular of these is the
synthetic genetic array [198], which allows the generation of a genome-
wide array of mutants, each also carrying a mutation in a query gene.
Such approaches provide information about the functions with which
a gene interacts, and can also highlight new potential therapeutic
strategies.
Yeast also havemore direct applications in the development of ther-
apies, and have been used in numerous and varied drug discovery
projects [199]. One particular advantage of yeast is the ability to use
the deletion libraries to identify drug targets by analysing the effect of
a drug on the ﬁtness proﬁle of the library [200], greatly streamlining
phenotypic drug screening.
15. Modelling NCLs in yeast
Both budding and ﬁssion yeast have been used extensively to study
the underlying biology of NCLs. CLN3 and CLN10 are conserved in
budding yeast, whereas ﬁssion yeast has orthologues of CLN1, CLN3
and CLN10. In addition, budding yeast has a known orthologue of
ATP13A2 (CLN12), one of the most recently identiﬁed NCL genes [201].
Much work in yeast has focused on the budding and ﬁssion yeast
orthologues of CLN3 (BTN1 and btn1 respectively), which, like CLN3,are membrane proteins of unknown function. This work is reviewed in
detail in [3], and will be summarised brieﬂy here. Budding yeast BNT1 is
known to localise to the vacuole and Golgi, and has an established role
in vacuolar (the yeast lysosome) and cellular pH homeostasis, basic
amino acid transport and storage and nitric oxide production
[202–209]. Fission yeast btn1 displays the same localization pattern
as BTN1, and regulates vacuolar pH and morphology, cell polarity,
cell wall homeostasis, temperature sensitivity and osmotic homeo-
stasis [210–212]. Fission yeast has also been used to highlight the
different levels of function retained by different disease-causing mu-
tations modelled in btn1 [213] and the metabolic changes, including
increased glycolytic ﬂux and TCA cycle activity, seen upon loss of
btn1 [214]. It was also used to highlight a role for btn1 in membrane
and protein trafﬁcking [215]. Loss of btn1 has been shown to lead to
the mis-sorting of the vacuolar protein carboxypeptidase Y, through
processes both dependent on and independent of its sorting receptor
Vps10. These observationswere accompanied by changes inGolgi num-
ber, subcellular localization and morphology. A comparable role for
BTN1 has also been reported, with BTN1 regulating Golgi morphology
by modulating SNARE (SED5) phosphorylation by YCK3 [216]. Finally,
BTN1 has been demonstrated to have a role in phospholipid homeosta-
sis, in particular leading to a decrease in phosphatidylethanolamine
levels [217].
The budding yeast orthologue of CLN10 (PEP4) is also well studied.
CLN10/PEP4 encodes cathepsin D, a vacuolar hydrolase. Inwork discussed
in [3], PEP4 has been shown tomediate vacuolar proteasematuration and
vacuolar morphology [218]. PEP4 is also important in the maintenance of
cells in quiescence, with its expression increasing with cellular age [219].
Further, it has been shown that the catalytic activity of PEP4 protects
against apoptosis, through the degradation of damaged macromolecules,
while the pro-peptide protects against necrosis by promoting histone
hypoacetylation, and the retention of pro-necrotic factors in the nucleus
[220].
In more recent work, PEP4 has been demonstrated to be protective
against acetic acid induced apoptosis [221]. During acetic acid induced
stress, PEP4 translocates from the vacuolar lumen to the cytosol,
where it is required for mitochondrial degradation, and the protection
against oxidative damage that this affords. The catalytic activity of
PEP4 is required for mitochondrial degradation, in a process that relies
upon the mitochondrial AAC proteins, adenine nucleotide translocators
found in the mitochondrial inner membrane [222].
The recent identiﬁcation of ATP13A2 (CLN12) as the disease-causing
gene in a rare case of juvenile NCL has highlighted the relevance of a
number of yeast studies to NCL [201]. Many studies have investigated
the cell biology of the yeast orthologue of CLN12 (YPK9), focusing partic-
ularly on its role in an early onset familial Parkinsonism (Kufor–Rakeb
syndrome). CLN12 is a Golgi-resident P-type ATPase, a family of
proteins that includes cation transporters. Consistent with this, the
loss of YPK9 leads to sensitivity to cadmium, manganese, nickel and
selenium, suggesting a role in cation transport [223].
In a genome-wide overexpression screen, YPK9 was identiﬁed as a
suppressor of α-synuclein toxicity [224], the key component of Lewy
bodies in Parkinson's disease, which is also elevated in CLN3 disease
models [225]. Increased expression of YPK9 reduced the number of
intracellular α-synuclein inclusions, but not total levels of protein.
This effect was linked to a rescue of vesicular trafﬁcking defects,
allowing the exit of carboxypeptidase Y from the endoplasmic reticu-
lum. Disease causing mutations linked to Kufor–Rakeb syndrome led
to mis-localisation of YPK9 and prevented protection against toxicity.
A mutation abolishing ATPase activity, by contrast, did not affect locali-
zation but also prevented protection. In this study, loss of YPK9 was
again linked to manganese sensitivity.
In a separate genomewide screen, this time looking at the interactions
of YPK9 itself, YPK9was shown to interact with a number of genes known
to be involved in protein trafﬁcking and manganese homeostasis [226].
A particularly well represented group were those linked to vesicle-
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VAM3, the Rab YPT6, vacuolar transport chaperone complex members,
and GLO3, an Arf GAP involved in ER–Golgi transport.16. Yeast models: a therapeutic focus
Pathology in the NCLs have been linked to awide array of cellular pro-
cesses but altered lipid homeostasis, particularly changes in sphingolipids
and ceramides, and lysosomal dysfunction are common themes for a
broad range of NCL genes [227]. Both processes have been studied exten-
sively in yeast, providing insights with relevance to disease and processes
that could be relevant to therapy.
Neurodegeneration can be thought of as a condition of impaired
cellular lifespan. Cellular age in yeast is generally measured using two
parameters: replicative lifespan (RLS), which is the number of divisions
a cell goes through before death, and chronological lifespan (CLS),
which is the amount of time a cell can survive in senescence [228]. In
some of the earliest work to highlight genes involved in cellular ageing,
budding yeast was used to identify LAG1 (Longevity-Assurance Gene 1),
a gene that, when deleted, caused a 50% increase in replicative lifespan.
LAG1 encodes a component of ceramide synthase, which catalyses
ceramide synthesis from dihydroceramide. Such an observation pro-
vides evidence that ceramide levels directly affect lifespan and interest-
ingly, ceramide levels are perturbed in a number of NCLs [227]. CLN8
itself shares homology with LAG1, containing a TLC (TRAM–Lag1p–
CLN8) domain, suggesting a potential role in ceramide synthesis.
Further, the human homologs of LAG1 can complement aspects of the
loss of CLN9 [229].
The link between sphingolipids and cellular ageing extends beyond
LAG1. IPT1, which catalyses the production of the terminal sphingolipid
mannose-(inositol-P)2-ceramide, increases CLS when deleted [230],
and ISC1, an inositol phosphosphingolipid phospholipase C that pro-
duces ceramides, shortens CLSwhen deleted [231]. Lifespan in the latter
deletion strain was greatly improved by deletion of SIT4 that codes for a
phosphatase positively regulated by ceramides [232] This suggests a
link between the lifespan-altering effects of ceramides and downstream
signalling processes. Interestingly, SIT4 is involved in a broad range of
range of processes linked to NCL including; protein trafﬁcking [233],
glycogen metabolism [234], heat-shock functions, cytoskeletal organi-
sation and ribosome biogenesis [235], and vacuolar homeostasis [236].
The link between vacuolar homeostasis and cellular lifespan is not
limited to ceramide-dependent processes. A study of how amino acid
deprivation increases lifespan in yeast indicated that methionine with-
drawal increases vacuolar acidiﬁcation in a manner dependent upon
autophagy. The authors then went on to demonstrate that increasing
vacuolar acidiﬁcation alone was sufﬁcient to increase lifespan [237],
providing evidence for a key role of vacuolar function in longevity. As
well as lowpH in the vacuole being protective against ageing, increasing
pH has been shown to be a part of normal ageing in budding yeast.
Increasing vacuolar pH has been demonstrated to lead to a decrease in
vacuolar amino acid storage and was also coupled with an increase in
mitochondrial dysfunction [238]. This link between vacuolar pH and
mitochondrial dysfunction provides a key link between vacuolar chang-
es, as observed in models for NCL, and defects known to contribute cell
death with cellular increasing age [239].
Yeast represent the simplest established model for eukaryotic cell
biology, allowing the study of cellular processes at a depth not afforded
by other systems. Further, the conservation of NCL genes in such a sim-
ple system suggests that they regulate fundamental cellular functions,
and provides the opportunity to utilise the advantages of the yeast
model. This approach has provided disease-relevant insights into the
roles of CLN3, CLN10 and the newly identiﬁed CLN12. In addition, the
level of information available regarding metabolic, biosynthetic and
signalling pathways in yeast species can provide valuable information
about processes involved in disease. In this review, such informationregarding sphingolipid biosynthesis and vacuolar function has also
been explored.
17. Emerging models for NCLs
There are relatively fewmodels available for the study of adult onset
NCLs. Beyond the cathepsin F (CLN13) knock-out mouse model for type
B Kufs disease [240], and the DNAJC5 (CLN4) knock-out mouse, which
provides a model for autosomal-dominant adult-onset NCL [241],
there are few options for the study of these conditions.
The nematode worm Caenorhabditis elegans provides a very simple
multicellular eukaryotic model system with a highly stereotyped and
deﬁned development and body plan [242]. C. elegans has orthologues
of CLN3 and CLN10, however little work has been done to study these
genes in the nematode (reviewed in [243]). C. elegans however has
recently emerged as a potential model for autosomal-dominant adult-
onset NCL [244]. Nematodes lacking the orthologue of CLN4 (dnj-14),
which encodes the molecular chaperone cysteine string protein α,
exhibit reduced lifespan, locomotor defects and impaired neurotrans-
mitter release. Underlying this phenotype, the worms exhibited an
age-dependent decline in neuronal cell bodies, reduced neurite num-
bers and contorted neuronal processes, particularly in the head of the
animal. Among the neurons lost, sensory neurons were particularly af-
fected, leading to chemosensing defects.
The lifespan defect in these wormswas exploited to allow screening
for potential therapeutic compounds. Resveratrol was the only com-
pound to rescue this defect, in addition to giving a partial rescue of the
neurodegeneration and chemotaxis phenotypes. Resveratrol has been
described in the past as being beneﬁcial for lifespan and, although the
mechanism-of-action is unclear, it is known to activate the Sirtuin
class of histone deacetylases and may act as a phosphodiesterase
(PDE) inhibitor [245]. Consistent with a role as a PDE inhibitor, the
rescue elicited byResveratrolwasmimicked by a knownPDEantagonist
Rolipram and consistent with this being the main therapeutic mecha-
nism of Resveratrol in this case, the deletion of Sirtuin sir-2.1 did not
affect this rescue. These observations provide key information about
the biology of CLN4 deﬁciency, aswell as a new therapeuticmechanism.
The social amoeba Dictyostelium discoideum is another very well-
established eukaryoticmodel organism.Dictyostelium has been success-
fully used in a number of studies to examine the role of genes associated
with neurodegenerative disorders [246–248], however it has only
recently been used in the study of NCLs. In a recent study, however,
the role of the Dictyostelium orthologue of CLN3 (Cln3) was explored
[249]. Cln3 was shown to localise to the vacuolar and endocytic com-
partments of Dictyostelium, consistent with observations in other
model systems. Cells lacking Cln3 exhibited altered trafﬁcking and pro-
cessing of autocrine proliferation repressor (AprA), leading to increased
proliferation, suggesting changes in protein trafﬁcking. Dictyostelium
also has a well characterised life-cycle, involving the formation of coor-
dinatedmulticellular aggregates (slugs), whichwas altered upon loss of
Cln3. These cells displayed a more rapid development through their
lifecycle and faster migrating slugs. All these pleiotropic effects were
rescued by expression of Cln3, or human CLN3, indicating that these
proteins are functional orthologues.
In a later study, Dictyostelium was also used to analyse the role of
CLN2 (TPP1) [250]. The Dictyostelium orthologue DdTpp1 was demon-
strated to contribute to the cleavage of TPP1 substrate, suggesting the
same role for ddTpp1 as TPP1. Both ddTpp1 and TPP1were also demon-
strated to localise to the lysosome of Dictyostelium. Like cells lacking
Cln3, cells lacking ddTpp1 exhibited amore rapidmulticellular develop-
ment, possibly suggesting overlapping roles. Cells lacking ddTpp1
displayed further developmental changes, exhibiting defects in spore
formation. These cells also exhibited clear defects in autophagy and
lysosomal function, with autophagic stimulation leading to a reduction
in cell size and viability and lysosomal perturbation leading to impaired
development. Finally, this later phenotype could be suppressed by the
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into themechanismof this defect and a potentialmechanismof suppress-
ing defects associated with the loss of TPP1.
This work in both C. elegans and Dictyostelium provides new informa-
tion about the roles of different NCL genes. Importantly this work
also opens up the repertoire of tools available to NCL research, providing
valuable new models for the study of these diseases.18. Concluding remarks
Model organisms have provided a wealth of information about the
processes that underlie the pathological changes observed in NCL. In
addition, suchmodels provide a means for the identiﬁcation and devel-
opment of much needed novel therapies. The work summarised in this
review also highlights the advantages of these models, and the value of
using a broad range of experimental systems in tackling complex
biological problems such as neurodegenerative disease. Finally, by
looking to broader related basic research in these models, we are able
to gain an insight into the cellular processes which may inﬂuence
disease.
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